Description: Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.
Home Page: www.gabather.com
Forskargatan 20J
Södertälje,
151 36
Sweden
Phone:
46 7 36 87 28 39
Officers
| Name | Title |
|---|---|
| Dr. Michael-Robin Witt | CEO & Director |
| Mr. Kristofer Svensson | Chief Financial Officer |
| Dr. Christine Ryan | Chief Operating Officer |
| Mr. Stefan Rehnmark | C S O |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 185.2895 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |